









Markets
/
Stocks
/
nasdaq-alks
/

Alkermes Plc

ALKS

34.910USD

+1.360+4.05%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

5.76BMarket Cap

16.91P/E TTM



Alkermes Plc

34.910

+1.360+4.05%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Alkermes Plc

Currency: USD Updated: 2026-02-06

Key Insights

Alkermes Plc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 1 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 43.81.In the medium term, the stock price is expected to remain stable.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Alkermes Plc's Score

Industry at a Glance

Industry Ranking

1 / 392

Overall Ranking

32 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Alkermes Plc Highlights

StrengthsRisks

Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 40.10% year-on-year.

Overvalued

The company’s latest PE is 16.91, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 175.23M shares, decreasing 0.01% quarter-over-quarter.

Held by Chuck Royce

Star Investor Chuck Royce holds 49.77K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.31.

Analyst Rating

Based on 17 analysts

Buy

Current Rating

43.813

Target Price

+30.59%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Alkermes Plc is 9.19, ranking 12 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 394.19M, representing a year-over-year increase of 4.24%, while its net profit experienced a year-over-year increase of 10.41%.

Score

Industry at a Glance

Previous score

9.19

Change



Financials

9.76

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.52

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.66

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Alkermes Plc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Alkermes Plc is 7.59, ranking 99 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is 16.91, which is 206.67% below the recent high of 51.86 and 299.04% above the recent low of -33.66.

Score

Industry at a Glance

Previous score

7.59

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 1/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Alkermes Plc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 45.00, with a high of 58.00 and a low of 30.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 17 analysts

Buy

Current Rating

43.813

Target Price

+30.59%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Alkermes Plc

ALKS

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Alkermes Plc is 9.57, ranking 6 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 37.16 and the support level at 30.80, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.21

Change

0.36

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.065

Buy

RSI(14)

65.804

Neutral

STOCH(KDJ)(9,3,3)

69.507

Neutral

ATR(14)

1.267

High Vlolatility

CCI(14)

89.472

Neutral

Williams %R

9.156

Overbought

TRIX(12,20)

0.738

Sell

StochRSI(14)

53.194

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

34.404

Buy

MA10

34.132

Buy

MA20

32.819

Buy

MA50

30.350

Buy

MA100

30.262

Buy

MA200

29.681

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Alkermes Plc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 117.54%, representing a quarter-over-quarter decrease of 3.78%. The largest institutional shareholder is The Vanguard, holding a total of 17.95M shares, representing 10.87% of shares outstanding, with 1.31% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

23.65M

-0.31%

The Vanguard Group, Inc.

Star Investors

18.13M

-1.76%

T. Rowe Price Associates, Inc.

Star Investors

10.05M

+1.92%

State Street Investment Management (US)

8.54M

+4.05%

Baker Bros. Advisors LP

8.09M

+26.22%

Renaissance Technologies LLC

Star Investors

6.29M

+8.30%

American Century Investment Management, Inc.

4.40M

+20.24%

Geode Capital Management, L.L.C.

4.06M

+0.94%

Dimensional Fund Advisors, L.P.

3.70M

+19.42%

JP Morgan Asset Management

3.62M

-8.29%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Alkermes Plc is 6.49, ranking 25 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.46. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Alkermes Plc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.